Treat patients with compassion, young doctors told
KALABURAGI
Medical Education Minister Sharanprakash Patil has emphasised the need for doctors to treat all patients equally, with compassion and confidence.
'Young doctors treat every patient equally irrespective of their socioeconomic backgrounds. You should never discriminate against any patient on the grounds of their social, economic, caste or religious background. You should always prioritise service over profit, especially when it comes to caring for underprivileged patients,' Dr. Patil said.
He was speaking at the Graduation Day for the 2019 MBBS batch of Gulbarga Institute of Medical Sciences (GIMS) late on Saturday.
Reiterating his government's commitment to improving medical education ecosystem in the State, Dr. Patil highlighted that the State government has invested significantly in medical education and student welfare.
'Our government is spending a lot of money on medical graduates. You must give back to society. By treating patients with empathy and moral responsibility, doctors can demonstrate their social commitment. Especially those who are graduated from government medical colleges like you have a greater role to play. You must be an example for others in treating all patients equally with empathy and compassion,' he said.
Noting that Karnataka produces the highest number of doctors in the country, the Minister said that Indian doctors are in high demand globally and called upon the medical professionals to get ready to meet global demand and expectations.
'The world expects hard work, skill and dedication from you. These qualities must be reflected in your medical practice,' he added.
Expansion
Dr. Patil also announced that 800 new medical seats will be added in Karnataka from this academic year, with five new government medical colleges being established.
Pro-Chancellor of BLDE Deemed University, Vijayapura, Y.M. Jayaraj remarked that the 2019 batch holds a special place, having pursued their medical education during the COVID-19 pandemic and witnessed significant developments in the field of medicine during that challenging period.
GIMS Director Umesh S.R., Medical Superintendent Shivakumar C.S., Principal Ajaykumar G., Financial Advisor Bharati and Chief Administrative Officer Pramila were also present at the event.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Bupa weighs foray into private hospitals market in India
British health insurance major Bupa is looking to enter the fast-growing private hospital and healthcare market in India, currently dominated by players like Max Healthcare, Apollo Hospitals, Fortis, Narayana Health, and Medanta, as the company grows its engagement beyond the traditional insurance business (Niva Bupa), global CEO Inaki Ereno told TOI in an interview. Excerpts: How do you assess the Indian health insurance market in India? The Indian health insurance market is the most attractive and best in the world. It's still under-penetrated, and we believe there will be many more people requiring private medical insurance. We need more beds, more hospitals, more clinics, and more insurance here... In terms of our own growth, it's been 35% over the last three years. We're clearly seeing a massive opportunity. In markets like Europe, UK, Australia , Latin America, you have a Bupa Payvider programme where you provide not just insurance and easy claims processing, but also a network of healthcare providers. These include dental and mental health clinics, and hospitals. Any plans to start hospitals and such other services in India? With Payvider, we are not just insurers but also providers. Of the claims that our patients go through, we always want around 25% in a place called Bupa - in a Bupa clinic, in a Bupa hospital, in a Bupa digital place. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Brass Idols - Handmade Brass Statues for Home & Gifting Luxeartisanship Buy Now Undo This helps us to learn the cost of things, and also allows us to personalise the service. It is too soon to talk about India. I cannot commit yet on the dates but, yes, you can expect that Bupa will keep investing here... we do have a plan, a commitment to study the situation and be ambitious and come up with something big. We believe that 25% of the activity that we do should be run in a place like Bupa. Inflation in health costs is a concern for customers, which also sees policy costs go up. Your views? When it comes to the cost of claims, there is inflation across the world. This is why developing a private medical insurance market helps everybody. When you have more people into private medical insurance, that helps lower costs of claims. Normally, premiums go up with inflation. So, they will not reduce. Are we expecting a big increase in premiums? The answer is no. We expect premiums to go in line with the Consumer Price Index (CPI). Apart from metros and bigger cities, how do you see the opportunity in Tier 2 and Tier 3 towns and rural India? We are clearly targeting markets beyond the top 50-60 cities. We think there's a massive opportunity to get people into the fold of insurance. India is at a very nascent stage, and awareness is still low with respect to health insurance. India is a growing country, with lots of construction and other infrastructure activities happening. Do you think that dust, pollution, and long traffic snarls in congested cities create health hazards for people? The answer is yes, though no one can make a direct correlation in elements like these. But we are working with the Norman Foster Foundation to understand what is the impact that living in a particular city has on your health, including in Delhi. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
5 hours ago
- Time of India
6 more deaths tied to Covid take India toll since January to 65
NEW DELHI: Six more Covid-related deaths were reported in the last 24 hours, the Union health ministry said on Sunday. The country's total Covid count has crossed the 6,000-mark, with 769 fresh cases being reported in the last 48 hours, revealed data released by the ministry. Kerala continues to be the most affected state, followed by Gujarat, West Bengal and Delhi. In all, there are 6,133 active Covid cases in the country. With the latest casualties, the Covid death toll since Jan has gone up to 65. Maharashtra has recorded the maximum fatalities (18), followed by Kerala (15) and Delhi (7). Due to the rising number of cases, Centre is conducting mock drills to check facility-level preparedness and has instructed all states to ensure availability of oxygen, isolation beds, ventilators, and essential medicines, official sources said. However, most cases are mild and are being managed under home care, they stressed. A series of technical review meetings were held on June 2 and 3, under the chairpersonship of director general of health services (DGHS) Dr Sunita Sharma, with representatives of Disaster Management Cell, Emergency Management Response Cell, National Centre for Disease Control, Indian Council of Medical Research, Integrated Disease Surveillance Programme, and central govt hospitals in Delhi and with representatives of states and UTs to evaluate the situation and preparedness measures.
Economic Times
5 hours ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
